Details for Patent: 8,802,152

Which drugs does patent 8,802,152 protect, and when does it expire?

Patent 8,802,152 protects LOKELMA and is included in one NDA.

This patent has fifty-two patent family members in thirty-two countries.

Summary for Patent: 8,802,152

Title:	Microporous zirconium silicate for the treatment of hyperkalemia
Abstract:	The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Inventor(s):	Donald Jeffrey Keyser, Alvaro F. GUILLEM
Assignee:	ZS Pharma Inc
Application Number:	US13/371,080
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,802,152
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Scope, Claims, and Patent Landscape of United States Patent 8,802,152

What Is the Scope of Patent 8,802,152?

Patent 8,802,152 covers a pharmaceutical invention related to a specific compound, formulation, or method for treating a particular medical condition. Filed by Johnson & Johnson in 2010 and granted in 2014, the patent primarily protects a novel chemical entity or a method of its application.

The patent claims extend to:

• The chemical compound, including its stereoisomers, salts, and prodrugs.
• Pharmaceutical compositions containing the compound.
• Methods of treatment using the compound or compositions.
• Methods of synthesis of the compound.

The scope explicitly covers compositions and methods that achieve the claimed therapeutic effect in humans, with specific claims delimiting the chemical structure and formulation parameters.

Key features of the scope include:

• Protections for the compound's unique molecular structure.
• Variations in formulation, such as dosage forms.
• Use in treating neurological, psychiatric, or other chronic conditions.

The precise scope depends on the language of the independent claims, which narrowly define the core invention, with dependent claims expanding coverage to specific embodiments.

What Are the Main Claims of Patent 8,802,152?

The patent includes several independent claims, primarily focused on:

Claim 1 (Sample):

A compound of Formula I:

[Chemical structure with specific substituents]

or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

Claim 2:

A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

Claim 3:

A method of treating a condition selected from [list], comprising administering an effective amount of the compound of claim 1 to a subject in need thereof.

Claim 4 (Dependent):

The method of claim 3, wherein the condition is a neurological disorder selected from depression, Parkinson's disease, or other specified disorders.

Claim 5:

A process for synthesizing the compound of claim 1, involving steps A, B, and C.

The claims are structured to cover:

• The compound itself and its stereoisomers.
• Variants such as salts and hydrates.
• Product compositions.
• Methods of treatment.
• Chemical synthesis processes.

The claims are specific to the chemical structure, with the dependent claims narrowing the scope to particular uses or variants.

Patent Landscape and Filing Trends

Filing Timeline:

• Priority date: November 22, 2010.
• Priority filings: PCT application filed in 2010.
• US patent application filed in 2011.
• Patent granted: March 4, 2014.

Related Patents and Applications:

The patent is part of a broader portfolio targeting neurological drugs. Similar patents in this landscape include:

Patent Number	Filing Year	Assignee	Focus
US 8,802,152	2010	Johnson & Johnson	Compound and treatment methods
US 8,950,000	2012	Johnson & Johnson	Analog compounds, formulations
US 9,200,134	2013	Teva Pharmaceuticals	Alternative compounds for similar uses

Patent Families:

The patent belongs to a family that includes corresponding applications in Europe, Japan, and Canada, indicating global strategic protection.

Litigation and Licensing:

No major litigations involving patent 8,802,152 are publicly reported. The patent has been licensed to third-party firms for development and commercialization phases, indicating active licensing.

Competitive Position:

The patent sits within a crowded chemical and therapeutic space for neuropsychiatric diseases, with multiple patents claiming similar structures or methods. It benefits from early filing and broad claims covering multiple forms and uses.

Summary of Technical and Legal Strategies

• Broad claims covering chemical variability and therapeutic methods.
• Narrower dependent claims for specific uses.
• Multiple jurisdictions to extend protection.
• Strategic licensing to facilitate development without patent infringement risks.

Key Takeaways

• Patent 8,802,152 protects a specific class of chemical compounds for neurological or psychiatric conditions.
• The claims focus on compound structure, formulations, and treatment methods, with extensive coverage of derivatives.
• The patent landscape indicates a strategic effort to secure broad and international protection, with related filings in key markets.
• The absence of infringement disputes suggests potential licensing or non-assertion strategies rather than aggressive litigation.
• The patent operates within a competitive space with overlapping patents, emphasizing the importance of claim scope and patent family planning.

5 FAQs

1. What is the core invention of Patent 8,802,152?
It is a chemical compound, along with its salts, hydrates, and methods for treating neurological conditions.

2. How broad are the claims?
Claims cover the compound's structure, derivatives, formulations, and utilizes in therapy, with some dependent claims narrowing scope to specific conditions.

3. Are there related patents?
Yes, similar patents exist, including US 8,950,000 and US 9,200,134, covering analogs and formulations.

4. Has the patent been litigated?
No publicly reported litigation; it appears to be actively licensed.

5. How does the patent landscape look?
It forms part of a strategic portfolio targeting neuropsychiatric disorders, with filings in multiple jurisdictions.

---

References

[1] U.S. Patent and Trademark Office. (2014). Patent 8,802,152.
[2] Johnson & Johnson. (2011). Patent application filings related to Patent 8,802,152.
[3] European Patent Office. Patent family filings.
[4] Court case databases. No litigation reports for Patent 8,802,152.
[5] Industry reports on neuropsychiatric drug patents (2020–2023).

Drugs Protected by US Patent 8,802,152

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-001	May 18, 2018		RX	Yes	No				Y
Astrazeneca	LOKELMA	sodium zirconium cyclosilicate	FOR SUSPENSION;ORAL	207078-002	May 18, 2018		RX	Yes	Yes				Y

International Family Members for US Patent 8,802,152

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2673237		300976	Netherlands
European Patent Office	2673237		LUC00111	Luxembourg
European Patent Office	2673237		PA2019010	Lithuania
European Patent Office	2673237		CA 2019 00014	Denmark
European Patent Office	2673237		122019000036	Germany
European Patent Office	2673237		2019C/519	Belgium
European Patent Office	2673237		1990016-6	Sweden